Peter Devine

Peter Devine has held a variety of roles in the venture capital and biotechnology industries since 2003. From 2003 to 2007, they served as a Non-Executive Director for various technology start-up companies. Peter was also a Non-Executive Director for various drug development biotechnology start-up companies from 2003 to 2008, including Spinifex Pharmaceuticals Pty Ltd (ACN 115 057 826) and Hatchtech Pty Ltd (ACN 098 559 409). From 2003 to 2018, they were the Chief Executive Officer of Uniseed, a venture fund operating at the Universities of Queensland, Sydney, NSW and Melbourne and the CSIRO. During this time, they were also a Responsible Manager & Authorised Representative and a Consultant / Investment Director. Since 2014, they have been a Non-Executive Director for ProGel Microgel Technology, BT Imaging Pty Ltd, Ferronova, and Hydrexia. In 2015, they became a Chair & Non-Executive Director for PERKii Enhanced Probiotics and Life Sciences Queensland Limited. In 2018, they became the Chair & Non-Executive Director of Kinoxis Therapeutics Pty Ltd.

Peter Devine's education history includes an MBA (Exec) from AGSM @ UNSW Business School from 1995 to 2000, a Graduate Diploma in Applied Finance from Kaplan Professional from 2009 to 2012, a Diploma in Financial Services (Financial Markets) from FINSIA from 2008 to 2009, a GAICD from Australian Institute of Company Directors in 2001, a PhD from The University of Queensland from 1989 to 1992, and a B.Sc (Hons) from UNSW in Biochemistry & Microbiology from 1979 to 1982.